GW Henssler & Associates Ltd. Sells 251 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GW Henssler & Associates Ltd. reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,817 shares of the biopharmaceutical company’s stock after selling 251 shares during the quarter. GW Henssler & Associates Ltd.’s holdings in Regeneron Pharmaceuticals were worth $12,692,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Rakuten Securities Inc. raised its holdings in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the period. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at $26,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $37,000. Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $39,000. Finally, Valley Wealth Managers Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $49,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $672.98 on Monday. The company has a 50 day moving average of $720.81 and a two-hundred day moving average of $922.87. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The company has a market cap of $73.95 billion, a price-to-earnings ratio of 16.65, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Evercore ISI reduced their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Morgan Stanley lowered their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price on the stock. Finally, Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.